ProMIS to Validate TDP-43 Antibodies for ALS Treatment

ProMIS to Validate TDP-43 Antibodies for ALS Treatment

305414

ProMIS to Validate TDP-43 Antibodies for ALS Treatment

ProMIS Neurosciences is advancing the development of antibodies against toxic TDP-43 protein clumps for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. Through lab and animal tests, ProMIS said in a press release, the company plans to validate its current antibodies, which include extracellular antibodies delivered through an into-the-vein injection, and intracellular antibodies given through gene therapy vectors that carry their genetic sequence. ProMIS also is planning additional studies to advance the development of…

You must be logged in to read/download the full post.